Galcanezumab Biosimilar - Research Grade

Human

CGRP

>1mg/ml

Human IgG4 (S228P/F234A/L235A)-Kappa

Fremanezumab Biosimilar - Research Grade (ICH5045)

https://www.imgt.org/mAb-DB/

ICH3002

P06881

796

RRID:AB_2921588

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of galcanezumab, a humanized monoclonal antibody that binds the calcitonin gene-related peptide (CGRP) ligand. It is supplied for research use only (RUO) and is not the clinical drug; it is not intended for human or veterinary use. Built around the CGRP target with a human IgG4 (S228P/F234A/L235A)-kappa framework, the effector-attenuating substitutions make it useful as a tool for studying ligand engagement without confounding Fc-mediated activity. Typical research applications include serving as a well-characterized positive control or reference antibody in binding and neutralization assays, as a capture or detection reagent in ligand-quantification workflows, as a benchmarking tool for developing or comparing new anti-CGRP binders, and as an isotype-matched comparator. It is available at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and in bulk milligram-to-gram quantities suitable for in-vitro assay development, screening panels, and preclinical characterization studies where lot-to-lot consistency and defined specificity are important. CGRP (calcitonin gene-related peptide) is a 37-amino-acid neuropeptide generated by tissue-specific alternative splicing of the CALC genes; alpha-CGRP arises from the CALCA transcript (UniProt P06881), which also encodes calcitonin, while beta-CGRP derives from CALCB. CGRP is a member of the calcitonin peptide family and is widely expressed in central and peripheral sensory neurons. It is one of the most potent known vasodilators and acts through the CGRP receptor, a complex of the calcitonin receptor-like receptor (CALCRL) with receptor activity-modifying protein 1 (RAMP1) and the intracellular receptor component protein, signaling largely via Gs and cyclic AMP. CGRP is a central mediator of trigeminovascular signaling and neurogenic inflammation, and its release during migraine attacks underpins the therapeutic rationale for ligand-neutralizing antibodies such as galcanezumab.

CGRP1, Alpha-type CGRP, Calcitonin gene-related peptide I, CGRP-I, Calcitonin gene-related peptide 1, CALCA, CALC1

Detects human CGRP. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Galcanezumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P, FALA

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Galcanezumab (anti-CGRP) Biosimilar

Q: Is the Galcanezumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Galcanezumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Galcanezumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Galcanezumab that binds human CGRP.